ESC Premium Access

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Topic: Lipids (Epidemiology and Prevention)
Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Sanofi/Regeneron and Amgen

Presentation

About the speaker

Doctor G Kees Hovingh

AMC Medical Research BV, Amsterdam (Netherlands (The))
1 presentation
0 follower

4 more presentations in this session

Introduction - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Speaker: Doctor M. Farnier (Dijon, FR)

Thumbnail

Understanding new PCSK9 outcome data: from the LDL-C hypothesis to LDL-c causality.

Speaker: Professor J. Chapman (Paris, FR)

Thumbnail

PCSK9 inhibition & CV events: review of recent and upcoming hard endpoint outcome trials.

Speaker: Professor P. Sever (London, GB)

Thumbnail

Discussion - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Speaker: Professor W. Koenig (Munich, DE) Doctor M. Farnier (Dijon, FR)

Thumbnail

Access the full session

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

Speakers: Doctor G. Hovingh, Doctor M. Farnier, Professor J. Chapman, Professor P. Sever, Professor W. Koenig...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk